Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation.

Le Loarer F, Cleven AHG, Bouvier C, Castex MP, Romagosa C, Moreau A, Salas S, Bonhomme B, Gomez-Brouchet A, Laurent C, Le Guellec S, Audard V, Giraud A, Ramos-Oliver I, Cleton-Jansen AM, Savci-Heijink DC, Kroon HM, Baud J, Pissaloux D, Pierron G, Sherwood A, Coindre JM, Bovée JVMG, Larousserie F, Tirode F.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0323-8. [Epub ahead of print]

PMID:
31383960
2.

Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes.

de Jong Y, Ingola M, Briaire-de Bruijn IH, Kruisselbrink AB, Venneker S, Palubeckaite I, Heijs BPAM, Cleton-Jansen AM, Haas RLM, Bovée JVMG.

Clin Sarcoma Res. 2019 May 28;9:9. doi: 10.1186/s13569-019-0119-0. eCollection 2019.

3.

Soft tissue aneurysmal bone cyst: six new cases with imaging details, molecular pathology, and review of the literature.

Song W, Suurmeijer AJH, Bollen SM, Cleton-Jansen AM, Bovée JVMG, Kroon HM.

Skeletal Radiol. 2019 Jul;48(7):1059-1067. doi: 10.1007/s00256-018-3135-x. Epub 2019 Jan 2. Review.

PMID:
30603771
4.

Molecular Pathology of Bone Tumors.

Lam SW, van IJzendoorn DGP, Cleton-Jansen AM, Szuhai K, Bovée JVMG.

J Mol Diagn. 2019 Mar;21(2):171-182. doi: 10.1016/j.jmoldx.2018.11.002. Epub 2018 Dec 18. Review.

PMID:
30572118
5.

Therapy-induced enrichment of cancer stem-like cells in solid human tumors: Where do we stand?

Martins-Neves SR, Cleton-Jansen AM, Gomes CMF.

Pharmacol Res. 2018 Nov;137:193-204. doi: 10.1016/j.phrs.2018.10.011. Epub 2018 Oct 11. Review.

PMID:
30316903
6.

Low-grade central fibroblastic osteosarcoma may be differentiated from its mimicker desmoplastic fibroma by genetic analysis.

Song W, van den Berg E, Kwee TC, Jutte PC, Cleton-Jansen AM, Bovée JVMG, Suurmeijer AJ.

Clin Sarcoma Res. 2018 Aug 23;8:16. doi: 10.1186/s13569-018-0104-z. eCollection 2018.

7.

Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCR-Based Targeted Next-Generation Sequencing.

Lam SW, Cleton-Jansen AM, Cleven AHG, Ruano D, van Wezel T, Szuhai K, Bovée JVMG.

J Mol Diagn. 2018 Sep;20(5):653-663. doi: 10.1016/j.jmoldx.2018.05.007. Epub 2018 Aug 20.

PMID:
30139549
8.

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.

Peterse EFP, Niessen B, Addie RD, de Jong Y, Cleven AHG, Kruisselbrink AB, van den Akker BEWM, Molenaar RJ, Cleton-Jansen AM, Bovée JVMG.

Br J Cancer. 2018 Apr;118(8):1074-1083. doi: 10.1038/s41416-018-0050-9. Epub 2018 Mar 26.

9.

High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.

Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, Veelken H, van Eijk R, Kraan W, Kersten MJ, van den Brand M, Stevens WBC, de Jong D, Abdul Hamid M, Tanis BC, Posthuma EFM, Nijland M, Diepstra A, Pals ST, Cleven AHG, Vermaat JSP.

Blood. 2018 May 3;131(18):2086-2089. doi: 10.1182/blood-2017-12-822817. Epub 2018 Mar 7. No abstract available.

PMID:
29514783
10.

Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.

Kostine M, Briaire-de Bruijn IH, Cleven AHG, Vervat C, Corver WE, Schilham MW, Van Beelen E, van Boven H, Haas RL, Italiano A, Cleton-Jansen AM, Bovée JVMG.

Oncoimmunology. 2017 Oct 26;7(2):e1386828. doi: 10.1080/2162402X.2017.1386828. eCollection 2018.

11.

Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers.

Veenstra R, Kostine M, Cleton-Jansen AM, de Miranda NF, Bovée JV.

Lab Invest. 2018 Jan;98(1):41-50. doi: 10.1038/labinvest.2017.128. Epub 2017 Nov 20. Review.

12.

IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft.

Martins-Neves SR, Paiva-Oliveira DI, Fontes-Ribeiro C, Bovée JVMG, Cleton-Jansen AM, Gomes CMF.

Cancer Lett. 2018 Feb 1;414:1-15. doi: 10.1016/j.canlet.2017.11.004. Epub 2017 Nov 8.

PMID:
29126913
13.

NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.

Peterse EFP, van den Akker BEWM, Niessen B, Oosting J, Suijker J, de Jong Y, Danen EHJ, Cleton-Jansen AM, Bovée JVMG.

Mol Cancer Res. 2017 Dec;15(12):1714-1721. doi: 10.1158/1541-7786.MCR-17-0293. Epub 2017 Aug 31.

14.

Increased Risk of Breast Cancer at a Young Age in Women with Fibrous Dysplasia.

Majoor BC, Boyce AM, Bovée JV, Smit VT, Collins MT, Cleton-Jansen AM, Dekkers OM, Hamdy NA, Dijkstra PS, Appelman-Dijkstra NM.

J Bone Miner Res. 2018 Jan;33(1):84-90. doi: 10.1002/jbmr.3286. Epub 2017 Sep 20.

15.

IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas.

Cleven AHG, Suijker J, Agrogiannis G, Briaire-de Bruijn IH, Frizzell N, Hoekstra AS, Wijers-Koster PM, Cleton-Jansen AM, Bovée JVMG.

Clin Sarcoma Res. 2017 May 4;7:8. doi: 10.1186/s13569-017-0074-6. eCollection 2017.

16.

A researcher's perspective on the quantity of osteosarcoma in vitro studies.

Peterse EFP, van Leeuwen TN, Cleton-Jansen AM.

J Bone Oncol. 2017 Apr 7;7:29-31. doi: 10.1016/j.jbo.2017.04.004. eCollection 2017 Jun.

17.

Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression.

Baglio SR, Lagerweij T, Pérez-Lanzón M, Ho XD, Léveillé N, Melo SA, Cleton-Jansen AM, Jordanova ES, Roncuzzi L, Greco M, van Eijndhoven MAJ, Grisendi G, Dominici M, Bonafede R, Lougheed SM, de Gruijl TD, Zini N, Cervo S, Steffan A, Canzonieri V, Martson A, Maasalu K, Köks S, Wurdinger T, Baldini N, Pegtel DM.

Clin Cancer Res. 2017 Jul 15;23(14):3721-3733. doi: 10.1158/1078-0432.CCR-16-2726. Epub 2017 Jan 4. Erratum in: Clin Cancer Res. 2018 Feb 1;24(3):724.

18.

Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.

Sundara YT, Kostine M, Cleven AH, Bovée JV, Schilham MW, Cleton-Jansen AM.

Cancer Immunol Immunother. 2017 Jan;66(1):119-128. doi: 10.1007/s00262-016-1925-3. Epub 2016 Nov 16.

19.

Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.

de Jong Y, van Maldegem AM, Marino-Enriquez A, de Jong D, Suijker J, Briaire-de Bruijn IH, Kruisselbrink AB, Cleton-Jansen AM, Szuhai K, Gelderblom H, Fletcher JA, Bovée JV.

Lab Invest. 2016 Oct;96(10):1128-37. doi: 10.1038/labinvest.2016.91. Epub 2016 Sep 12.

20.

No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone.

Peterse EF, Cleven AH, De Jong Y, Briaire-de Bruijn I, Fletcher JA, Danen EH, Cleton-Jansen AM, Bovée JV.

BMC Cancer. 2016 Jul 14;16:475. doi: 10.1186/s12885-016-2522-8.

21.

Hypoxia-related microRNA-210 is a diagnostic marker for discriminating osteoblastoma and osteosarcoma.

Riester SM, Torres-Mora J, Dudakovic A, Camilleri ET, Wang W, Xu F, Thaler RR, Evans JM, Zwartbol R, Briaire-de Bruijn IH, Maran A, Folpe AL, Inwards CY, Rose PS, Shives TC, Yaszemski MJ, Sim FH, Deyle DR, Larson AN, Galindo MA, Cleven AGH, Oliveira AM, Cleton-Jansen AM, Bovée JVMG, van Wijnen AJ.

J Orthop Res. 2017 May;35(5):1137-1146. doi: 10.1002/jor.23344. Epub 2016 Jun 28.

22.

The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report.

Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovée JVMG, Brennan B, Broto JM, Brugières L, Cleton-Jansen AM, Copland C, Dutour A, Fagioli F, Ferrari S, Fiocco M, Fleuren E, Gaspar N, Gelderblom H, Gerrand C, Gerß J, Gonzato O, van der Graaf W, Hecker-Nolting S, Herrero-Martín D, Klco-Brosius S, Kovar H, Ladenstein R, Lancia C, LeDeley MC, McCabe MG, Metzler M, Myklebost O, Nathrath M, Picci P, Potratz J, Redini F, Richter GHS, Reinke D, Rutkowski P, Scotlandi K, Strauss S, Thomas D, Tirado OM, Tirode F, Vassal G, Bielack SS.

Clin Sarcoma Res. 2016 Mar 16;6:3. doi: 10.1186/s13569-016-0043-5. eCollection 2016.

23.

Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype.

Kostine M, Cleven AH, de Miranda NF, Italiano A, Cleton-Jansen AM, Bovée JV.

Mod Pathol. 2016 Sep;29(9):1028-37. doi: 10.1038/modpathol.2016.108. Epub 2016 Jun 17.

24.

Targeting survivin as a potential new treatment for chondrosarcoma of bone.

de Jong Y, van Oosterwijk JG, Kruisselbrink AB, Briaire-de Bruijn IH, Agrogiannis G, Baranski Z, Cleven AH, Cleton-Jansen AM, van de Water B, Danen EH, Bovée JV.

Oncogenesis. 2016 May 9;5:e222. doi: 10.1038/oncsis.2016.33.

25.

Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.

de Graaff MA, de Rooij MA, van den Akker BE, Gelderblom H, Chibon F, Coindre JM, Marino-Enriquez A, Fletcher JA, Cleton-Jansen AM, Bovée JV.

Br J Cancer. 2016 May 24;114(11):1219-26. doi: 10.1038/bjc.2016.117. Epub 2016 May 3.

26.

MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation.

Baranski Z, Booij TH, Kuijjer ML, de Jong Y, Cleton-Jansen AM, Price LS, van de Water B, Bovée JV, Hogendoorn PC, Danen EH.

Genes Cancer. 2015 Nov;6(11-12):503-12.

27.

Tissue factor associates with survival and regulates tumour progression in osteosarcoma.

Tieken C, Verboom MC, Ruf W, Gelderblom H, Bovée JV, Reitsma PH, Cleton-Jansen AM, Versteeg HH.

Thromb Haemost. 2016 May 2;115(5):1025-33. doi: 10.1160/TH15-07-0541. Epub 2016 Jan 14.

28.

Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/β-catenin signaling.

Martins-Neves SR, Paiva-Oliveira DI, Wijers-Koster PM, Abrunhosa AJ, Fontes-Ribeiro C, Bovée JV, Cleton-Jansen AM, Gomes CM.

Cancer Lett. 2016 Jan 28;370(2):286-95. doi: 10.1016/j.canlet.2015.11.013. Epub 2015 Nov 11.

PMID:
26577806
29.

Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.

Cleven AH, Höcker S, Briaire-de Bruijn I, Szuhai K, Cleton-Jansen AM, Bovée JV.

Am J Surg Pathol. 2015 Nov;39(11):1576-83. doi: 10.1097/PAS.0000000000000512.

PMID:
26457357
30.

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin.

Baranski Z, de Jong Y, Ilkova T, Peterse EF, Cleton-Jansen AM, van de Water B, Hogendoorn PC, Bovée JV, Danen EH.

Oncotarget. 2015 Nov 3;6(34):36113-25. doi: 10.18632/oncotarget.5333.

31.

Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.

Verschoor AJ, Cleton-Jansen AM, Wijers-Koster P, Coffin CM, Lazar AJ, Nout RA, Rubin BP, Gelderblom H, Bovée JV.

Am J Surg Pathol. 2015 Dec;39(12):1701-7. doi: 10.1097/PAS.0000000000000510.

PMID:
26414222
32.

Osteosarcoma Stem Cells Have Active Wnt/β-catenin and Overexpress SOX2 and KLF4.

Martins-Neves SR, Corver WE, Paiva-Oliveira DI, van den Akker BE, Briaire-de-Bruijn IH, Bovée JV, Gomes CM, Cleton-Jansen AM.

J Cell Physiol. 2016 Apr;231(4):876-86. doi: 10.1002/jcp.25179. Epub 2015 Sep 9.

PMID:
26332365
33.

Mesenchymal stromal cells of osteosarcoma patients do not show evidence of neoplastic changes during long-term culture.

Buddingh EP, Ruslan SEN, Reijnders CMA, Szuhai K, Kuijjer ML, Roelofs H, Hogendoorn PCW, Maarten Egeler R, Cleton-Jansen AM, Lankester AC.

Clin Sarcoma Res. 2015 Jun 23;5:16. doi: 10.1186/s13569-015-0031-1. eCollection 2015.

34.

The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo.

Suijker J, Baelde HJ, Roelofs H, Cleton-Jansen AM, Bovée JV.

Oncotarget. 2015 Jun 20;6(17):14832-42.

35.

Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.

Suijker J, Oosting J, Koornneef A, Struys EA, Salomons GS, Schaap FG, Waaijer CJ, Wijers-Koster PM, Briaire-de Bruijn IH, Haazen L, Riester SM, Dudakovic A, Danen E, Cleton-Jansen AM, van Wijnen AJ, Bovée JV.

Oncotarget. 2015 May 20;6(14):12505-19.

36.

Expression of the immune regulation antigen CD70 in osteosarcoma.

Pahl JH, Santos SJ, Kuijjer ML, Boerman GH, Sand LG, Szuhai K, Cleton-Jansen A, Egeler RM, Boveé JV, Schilham MW, Lankester AC.

Cancer Cell Int. 2015 Mar 18;15:31. doi: 10.1186/s12935-015-0181-5. eCollection 2015.

37.

Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.

Baranski Z, Booij TH, Cleton-Jansen AM, Price LS, van de Water B, Bovée JV, Hogendoorn PC, Danen EH.

J Pathol. 2015 Jul;236(3):348-59. doi: 10.1002/path.4528. Epub 2015 Mar 30.

PMID:
25757065
38.

Gene expression profiling of giant cell tumor of bone reveals downregulation of extracellular matrix components decorin and lumican associated with lung metastasis.

Lieveld M, Bodson E, De Boeck G, Nouman B, Cleton-Jansen AM, Korsching E, Benassi MS, Picci P, Sys G, Poffyn B, Athanasou NA, Hogendoorn PC, Forsyth RG.

Virchows Arch. 2014 Dec;465(6):703-13. doi: 10.1007/s00428-014-1666-7. Epub 2014 Oct 11.

PMID:
25304290
39.

ENCCA WP17-WP7 consensus paper on teenagers and young adults (TYA) with bone sarcomas.

Wilhelm M, Dirksen U, Bielack SS, Whelan JS, Lewis IJ, Jürgens H, Ferrari S, Sundby Hall K, Cleton-Jansen AM, Stark D; ENCCA (European Network for Cancer research in Children and Adolescents).

Ann Oncol. 2014 Aug;25(8):1500-5. doi: 10.1093/annonc/mdu153. Epub 2014 Jun 24.

PMID:
24962703
40.

Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.

Pahl JH, Kwappenberg KM, Varypataki EM, Santos SJ, Kuijjer ML, Mohamed S, Wijnen JT, van Tol MJ, Cleton-Jansen AM, Egeler RM, Jiskoot W, Lankester AC, Schilham MW.

J Exp Clin Cancer Res. 2014 Mar 10;33:27. doi: 10.1186/1756-9966-33-27.

41.

Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy.

Kuijjer ML, van den Akker BE, Hilhorst R, Mommersteeg M, Buddingh EP, Serra M, Bürger H, Hogendoorn PC, Cleton-Jansen AM.

BMC Med Genomics. 2014 Jan 21;7:4. doi: 10.1186/1755-8794-7-4.

42.

Recurrent chromosome 22 deletions in osteoblastoma affect inhibitors of the Wnt/beta-catenin signaling pathway.

Nord KH, Nilsson J, Arbajian E, Vult von Steyern F, Brosjö O, Cleton-Jansen AM, Szuhai K, Hogendoorn PC.

PLoS One. 2013 Nov 13;8(11):e80725. doi: 10.1371/journal.pone.0080725. eCollection 2013.

43.

Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation.

Kansara M, Leong HS, Lin DM, Popkiss S, Pang P, Garsed DW, Walkley CR, Cullinane C, Ellul J, Haynes NM, Hicks R, Kuijjer ML, Cleton-Jansen AM, Hinds PW, Smyth MJ, Thomas DM.

J Clin Invest. 2013 Dec;123(12):5351-60. doi: 10.1172/JCI70559. Epub 2013 Nov 15.

44.

Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma.

van Oosterwijk JG, Anninga JK, Gelderblom H, Cleton-Jansen AM, Bovée JV.

Hematol Oncol Clin North Am. 2013 Oct;27(5):1021-48. doi: 10.1016/j.hoc.2013.07.012. Epub 2013 Aug 26. Review.

PMID:
24093174
45.

Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery.

Posthumadeboer J, Piersma SR, Pham TV, van Egmond PW, Knol JC, Cleton-Jansen AM, van Geer MA, van Beusechem VW, Kaspers GJ, van Royen BJ, Jiménez CR, Helder MN.

Br J Cancer. 2013 Oct 15;109(8):2142-54. doi: 10.1038/bjc.2013.578. Epub 2013 Sep 24.

46.

CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.

Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Le Cesne A, Hartgrink HH, Cleton-Jansen AM, Domont J, Bovée JV, Bonvalot S, Lev D, Gronchi A.

Cancer. 2013 Oct 15;119(20):3696-702. doi: 10.1002/cncr.28271. Epub 2013 Jul 31.

47.

Mesenchymal stem cell transformation and sarcoma genesis.

Xiao W, Mohseny AB, Hogendoorn PC, Cleton-Jansen AM.

Clin Sarcoma Res. 2013 Jul 23;3(1):10. doi: 10.1186/2045-3329-3-10.

48.

IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma.

Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PC, Cleton-Jansen AM.

BMC Cancer. 2013 May 20;13:245. doi: 10.1186/1471-2407-13-245.

49.

Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.

de Graaff MA, Cleton-Jansen AM, Szuhai K, Bovée JV.

Hum Pathol. 2013 Aug;44(8):1597-604. doi: 10.1016/j.humpath.2013.01.006. Epub 2013 Mar 19.

PMID:
23517922
50.

Genome-wide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor.

Kuijjer ML, Hogendoorn PC, Cleton-Jansen AM.

Int J Cancer. 2013 Dec 1;133(11):2512-21. doi: 10.1002/ijc.28124. Epub 2013 Mar 16. Review.

Supplemental Content

Loading ...
Support Center